Abstract: Methods of treating, preventing and/or retarding the progression of cognitive decline, in human subjects having a disease characterized by deposition of A? in the brain including Alzheimer's disease, Down's syndrome, and cerebral amyloid angiopathy, using anti-N3pGlu A? antibodies.

Abstract: The invention is directed to treatment or prevention of a disease characterized by deposition of A? in the brain using anti-A? antibodies. The diseases that can be treated or prevented include, e.g., Alzheimer's disease, Down's syndrome, and cerebral amyloid angiopathy. The invention is also related to, in some aspects, to selecting a human subject based on the tau burden in the human subjects' brain, who is responsive to treatment or prevention of a disease characterized by deposition of A? in the brain that includes administering anti-A? antibodies. The invention is also related to human subjects who have one or two alleles of APOE e4.

Abstract: The present disclosure relates to IL-34 antibodies, compositions comprising the same, and methods of using the antibodies and or compositions thereof for treating immune-mediated diseases such as neurodegenerative diseases, for example Alzheimer's Disease or a tauopathy disease.

Abstract: The invention is directed to treatment or prevention of a disease characterized by deposition of A? in the brain using anti-N3pGlu A? antibodies. The diseases that can be treated or prevented include, e.g., Alzheimer's disease, Down's syndrome, and cerebral amyloid angiopathy. The invention, in some aspects, is related to doses and dosing regimens useful for such treatments. The invention is also related to, in some aspects, human subjects who are responsive to treatment or prevention of a disease characterized by deposition of A? in the brain using anti-N3pGlu A? antibodies. The invention is also related to human subject who have one or two alleles of APOE4.

Abstract: The present disclosure relates to IL-34 antibodies, compositions comprising the same, and methods of using the antibodies and or compositions thereof for treating immune-mediated diseases such as neurodegenerative diseases, for example Alzheimer’s Disease or a tauopathy disease.

Abstract: Tracers for imaging distribution of reactive oxygen species (ROS) are disclosed. The tracers include radiolabeled dihydroethidine (DHE) analogues. Further disclosed are uses of the compounds, including methods of imaging tissue distribution of ROS in vivo by positron emission tomography (PET). Methods of synthesizing the compounds are also disclosed.

Abstract: Tracers for imaging distribution of reactive oxygen species (ROS) are disclosed. The tracers include radiolabeled dihydroethidine (DHE) analogues. Further disclosed are uses of the compounds, including methods of imaging tissue distribution of ROS in vivo by positron emission tomography (PET). Methods of synthesizing the compounds are also disclosed.